FDA Clearance Tracker · P120005-S031
DEXCOM G4 PLATINUM (PEDIATRIC) CONTINUOUS GLUCOSE MONITORING SYSTEM
Last checked: Nov 20, 2026Latest source record: May 22, 2015 (this decision)Source: openFDAMethods & limitations
Decided
May 22, 2015
Approved
Time to decision
177 days
Received Nov 26, 2014. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Panel Track
Device class
Class III
The decision
- FDA number
- P120005-S031
- Device name
- DEXCOM G4 PLATINUM (PEDIATRIC) CONTINUOUS GLUCOSE MONITORING SYSTEM
- Applicant
- Dexcom, Inc.
- Applicant location
- San Diego, CA
- Received
- Nov 26, 2014
- Decided
- May 22, 2015
- Decision
- Approved
- Supplement type
- Panel Track
- Reason for supplement
- Change Design/Components/Specifications/Material
- Original approval
- P120005
Device type
- Device type
- Sensor, glucose, invasive (MDS)
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
APPROVAL FOR THE DEXCOM G4¿ PLATINUM (PEDIATRIC) CONTINUOUS GLUCOSE MONITORING SYSTEM. THIS DEVICE IS A GLUCOSE MONITORING DEVICE INDICATED FOR DETECTING TRENDS AND TRACKING PATTERNS IN PERSONS AGES 2 TO 17 YEARS WITH DIABETES. THE SYSTEM IS INTENDED FOR SINGLE PATIENT USE AND REQUIRES A PRESCRIPTION. THE DEXCOM G4 PLATINUM (PEDIATRIC) SYSTEM IS INDICATED FOR USE AS AN ADJUNCTIVE DEVICE TO COMPLEMENT, NOT REPLACE, INFORMATION OBTAINED FROM STANDARD HOME GLUCOSE MONITORING DEVICES. THE DEXCOM G4 PLATINUM (PEDIATRIC) SYSTEM AIDS IN THE DETECTION OF EPISODES OF HYPERGLYCEMIA AND HYPOGLYCEMIA, FACILITATING BOTH ACUTE AND LONG-TERM THERAPY ADJUSTMENTS, WHICH MAY MINIMIZE THESE EXCURSIONS. INTERPRETATION OF THE DEXCOM G4 PLATINUM (PEDIATRIC) SYSTEM RESULTS SHOULD BE BASED ON THE TRENDS AND PATTERNS SEEN WITH SEVERAL SEQUENTIAL READINGS OVER TIME.
Source documents
Other decisions for Dexcom, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K262472 · Decided Aug 11, 2026 · 25 days after receipt
Device type: Integrated Continuous Glucose Monitor For Non-Intensive Glucose Management, Over-The-Counter (SBH) · Laboratory Medicine & Pathology
K260935 · Decided Jun 12, 2026 · 84 days after receipt
Device type: Integrated Continuous Glucose Monitor For Non-Intensive Glucose Management, Over-The-Counter (SBH) · Laboratory Medicine & Pathology
- Dexcom G7 Continuous Glucose Monitoring System;Dexcom G7 15 Day Continuous Glucose Monitoring System510(k)
K261402 · Decided Jun 8, 2026 · 40 days after receipt
Device type: Integrated Continuous Glucose Monitoring System, Factory Calibrated (QBJ) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.